Dyne Therapeutics saw the highest growth of 3.74% in patent filings in May and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.23% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Dyne Therapeutics‘s patent filings and grants. Buy the databook here.
Dyne Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with 13 publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 40% of filings. The European Patent Office(EPO), United States(US), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where Dyne Therapeutics is filings its patents. Among the top granted patent authorities, Dyne Therapeutics has 100% of its grants in United States(US).
In terms of grant share, Dyne Therapeutics stands first among its competitors followed by and .
Patents related to rare diseases lead Dyne Therapeutics's portfolio
Dyne Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Duchenne muscular dystrophy related patents lead Dyne Therapeutics portfolio followed by myotonic dystrophy, and facioscapulohumeral muscular dystrophy (fshd)
Dyne Therapeutics has highest number of patents in duchenne muscular dystrophy followed by myotonic dystrophy, facioscapulohumeral muscular dystrophy (fshd), muscular dystrophy, and asthenia. For duchenne muscular dystrophy, nearly 36% of patents were filed and 22% of patents were granted in Q2 2024.
For comprehensive analysis of Dyne Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.